Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients

Condition(s) targeted: Cystic Fibrosis

Intervention: non-interventional study (Other)

Phase: N/A

Status: Recruiting

Sponsored by: University Hospital Muenster

Official(s) and/or principal investigator(s):
Barbara C Kahl, MD, Principal Investigator, Affiliation: Dept. Med. Microbiology, University Clinics Muenster, Germany

Overall contact:
Barbara C Kahl, MD, Phone: 49-251-835-5381, Email: kahl@uni-muenster.de

Staphylococcus aureus is not only one of the first pathogens infecting the airways of cystic fibrosis (CF) patients, but also a highly prevalent microorganism (>60% of all CF patients; European and American CF registries; (4,25), which often persists for several years in the respiratory tract of CF patients.

The purpose of this study is to dissect infection by S. aureus from colonization. Therefore, the following non-interventional prospective, longitudinal multicenter study will be conducted to develop the following hypothesis:

CF patients with high bacterial loads are more likely to be infected by S. aureus than patients with low bacterial loads.

Primary endpoint: bacterial load of sputum cultures

Secondary endpoints:

- nasal carriage

- molecular analysis of S. aureus (Monoclonal/polyclonal)

- serum: S. aureus-specific antibodies, S100A12, IL-8, TNF-alpha

- sputum: S100A12, IL-8, myeloperoxidase

- S. aureus therapy regimens

- lung function tests: FEV1, deltaFVC , deltaMEF25

- BMI development

Inclusion criteria: S. aureus cultures for more than 6 months within the last year, children (>6 years) and patients, who are able to perform lung function tests Exclusion criteria: P. aeruginosa and/or B. cepacia cultures from the specimens for more than 6 months within the last year before recruitment or during the study period In addition to microbiological investigations and clinical laboratory tests, the actual clinical situation will be evaluated and reported during the study period. The results of this observational study will be used to carefully plan a clinical interventional study. Furthermore, with the results it might be possible to characterize a subpopulation of patients, which is at greater risk for S. aureus infections.

Official title: Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients, a Non-Interventional, Prospective, Longitudinal Multicenter Study.

Study design: Case-Only, Prospective

Primary outcome: bacterial load of sputum cultures [high (>/= 1000000CFU/ml); low (<1000000CFU/ml)]

Secondary outcome: antibody titres against S. aureus specific antigens; S100A12, IL-8, TNF-alpha, CRP

Detailed description: Protocol synopsis Title: Dissection of Staphylococcus aureus infection from colonization in cystic fibrosis patients. A non-interventional prospective, 2-year longitudinal multicenter study

Study objectives: The aim of the study is to dissect S. aureus infection from colonization of the pathogen in airway secretions of CF patients during a 2 year period by means of a non-interventional, prospective, longitudinal multicenter study.

The following hypothesis will be developed:

CF patients with high bacterial loads are more likely to be infected by S. aureus than patients with low bacterial loads.

Definition of infection:

- change in volume, colour or consistency of sputum (exacerbation)

- increased cough

- malaise, fatigue or lethargy

- body temperature more than 38°C

- new or increased hemoptysis

- anorexia or weight loss

- sinus pain or tenderness

- change in sinus discharge

- change in chest sounds

- ten percent decrease in pulmonary function from a previous recorded value (FEV1, MEF25)

- radiographic changes indicative of pulmonary infection

Primary endpoint: bacterial load of sputum cultures [high (>/= 106CFU/ml); low (<106CFU/ml)]

Secondary endpoints are:

- assessment of nasal S. aureus carriage

- serum samples: antibody titres against S. aureus specific antigens; S100A12,

IL-8,TNF-alpha, CRP

- molecular analysis of S. aureus colonization/infection (monoclonal or heteroclonal)

- sputa analysis: activity of S100A12, IL-8 and myeloperoxidase

- antibiotic treatment regimens against S. aureus

- body mass index

- lung function tests: FEV1, deltaFVC, deltaMEF25

Extensive microbiological investigations will be performed when the patients are seen at their regular visits in the outpatient clinics or if exacerbations occur. During the study period of 2 years, at least 8 visits to the outpatient clinic should be recorded. The following clinical parameters will be documented:

- lung function

- body mass index (weight/height)

- antibiotic treatment Diagnosis: CF and positive S. aureus cultures for more than 6

months within the last year Localisation of the study: multicenter study in Germany Number of centers: Seven centres agreed already to participate in the study. More centers have been and will be contacted.

Design: non-interventional prospective, longitudinal multicenter study Planned number of patients/volunteers: 228 Inclusion criteria: positive S. aureus cultures for more than 6 months within the last year; children (>6 years) and patients with CF, who are able to perform lung function tests Exclusion criteria: Pseudomonas aeruginosa and/or Burkholderia cepacia colonization or infection for more than 6 months within the last year before recruitment; patients who have not been colonized with these pathogens before but acquire them within the study period and are colonized/infected for more than 6 months during the observation period

Minimum age: 6 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- positive S. aureus cultures for more than 6 months within the last year; children (>6

years) and patients with CF, who are able to perform lung function tests

Exclusion Criteria:

- Pseudomonas aeruginosa and/or Burkholderia cepacia colonization or infection for more

than 6 months within the last year before recruitment; patients who have not been colonized with these pathogens before but acquire them within the study period and are colonized/infected for more than 6 months during the observation period

Barbara C Kahl, MD, Phone: 49-251-835-5381, Email: kahl@uni-muenster.de

University Clinics Muenster, Muenster 48149, Germany; Recruiting
Angelika Duebbers, MD, Email: adue@uni-muenster.de
Angelika Duebbers, MD, Principal Investigator

University Clinics Essen, Essen 45122, Germany; Not yet recruiting
Uwe Mellies, MD, Phone: 49-201-723-3355, Email: Uwe.Mellies@uk-essen.de
Uwe Mellies, MD, Principal Investigator

Ruhrlandklinik Essen-Heidhausen, Essen 45239, Germany; Not yet recruiting
Helmut Teschler, MD, Phone: 49-201-937-0, Email: teschlerh@t-online.de
Helmut Teschler, MD, Principal Investigator

Heinrich-Heine University Duesseldorf, Duesseldorf 40225, Germany; Not yet recruiting
Antje Schuster, MD, Phone: 49-211-811-8297, Email: Schuster@med.uni-duesseldorf.de
Antje Schuster, MD, Principal Investigator

Medical School Hannover, Hannover 30625, Germany; Not yet recruiting
Manfred Ballmann, MD, Phone: 49-511-532-3220, Email: Ballmann.Manfred@mh-hannover.de
Sibylle Junge, MD, Phone: 49-511-532-3220, Email: Junge.Sibylle@MH-Hannover.de
Manfred Ballmann, MD, Principal Investigator

Dr. Peter Kuester, Muenster 48153, Germany; Not yet recruiting
Peter Kuester, MD, Phone: 49-251-976-2930, Email: p.kuester@clemenshospital.de
Peter Kuester, MD, Principal Investigator

University Clinics Jena, Jena 07743, Germany; Not yet recruiting
Jochen Mainz, MD, Email: Jochen.Mainz@med.uni-jena.de
Jochen Mainz, MD, Sub-Investigator

Children's Hospital Park Schoenfeld, Kassel 34121, Germany; Not yet recruiting
Martin Schebek, MD, Email: martin.schebek@park-schoenfeld.de
Martin Schebek, MD, Sub-Investigator

Children's Hospital Osnabrueck, Osnabrueck 49082, Germany; Not yet recruiting
Ruediger Szczepanski, MD, Email: szczepanski@kinderhospital.de
Ruediger Szczepanski, MD, Email: szczepanski@kinderhospital.de
Ruediger Szczepanski, MD, Sub-Investigator

Charite Berlin Campus Benjamin Franklin, Berlin 12200, Germany; Not yet recruiting
Doris Staab, MD, Phone: +49-30-84454932, Email: doris.staab@charite.de
Doris Staab, MD, Principal Investigator

University Clinics Tuebingen, Tuebingen 72076, Germany; Not yet recruiting
Joachim Riethmueller, MD, Phone: +49-7071-29 81391, Email: joachim.riethmueller@uni-tuebingen.de
Joachim Riethmueller, MD, Principal Investigator

University Clinics Koeln, Koeln 50924, Germany; Not yet recruiting
Ernst Rietschel, MD, Phone: +49-221-4786172, Email: ernst.rietschel@uk-koeln.de
Ernst Rietschel, MD, Principal Investigator

Starting date: July 2008
Ending date: December 2010
Last updated: August 6, 2008